Logo image of ALVIO.PA

VALERIO TX (ALVIO.PA) Stock Fundamental Analysis

EPA:ALVIO - Euronext Paris - Matif - FR0010095596 - Common Stock - Currency: EUR

0.053  0 (-8.3%)

Fundamental Rating

1

Overall ALVIO gets a fundamental rating of 1 out of 10. We evaluated ALVIO against 68 industry peers in the Biotechnology industry. Both the profitability and financial health of ALVIO have multiple concerns. ALVIO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALVIO has reported negative net income.
ALVIO had a negative operating cash flow in the past year.
ALVIO had negative earnings in 4 of the past 5 years.
ALVIO had a negative operating cash flow in each of the past 5 years.
ALVIO.PA Yearly Net Income VS EBIT VS OCF VS FCFALVIO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -67.00%, ALVIO is doing worse than 67.65% of the companies in the same industry.
With a Return On Equity value of -488.76%, ALVIO is not doing good in the industry: 70.59% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -67%
ROE -488.76%
ROIC N/A
ROA(3y)-38.08%
ROA(5y)-40.32%
ROE(3y)-81.06%
ROE(5y)-87.11%
ROIC(3y)N/A
ROIC(5y)N/A
ALVIO.PA Yearly ROA, ROE, ROICALVIO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

ALVIO has a better Gross Margin (74.75%) than 70.59% of its industry peers.
ALVIO's Gross Margin has declined in the last couple of years.
ALVIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.31%
GM growth 5Y-6.1%
ALVIO.PA Yearly Profit, Operating, Gross MarginsALVIO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

More info and screens

0

2. Health

2.1 Basic Checks

ALVIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALVIO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALVIO has more shares outstanding
Compared to 1 year ago, ALVIO has a worse debt to assets ratio.
ALVIO.PA Yearly Shares OutstandingALVIO.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
ALVIO.PA Yearly Total Debt VS Total AssetsALVIO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.06, we must say that ALVIO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.06, ALVIO is not doing good in the industry: 66.18% of the companies in the same industry are doing better.
ALVIO has a Debt/Equity ratio of 2.88. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.88, ALVIO is not doing good in the industry: 69.12% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.88
Debt/FCF N/A
Altman-Z -4.06
ROIC/WACCN/A
WACC7.06%
ALVIO.PA Yearly LT Debt VS Equity VS FCFALVIO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

ALVIO has a Current Ratio of 0.90. This is a bad value and indicates that ALVIO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ALVIO (0.90) is worse than 76.47% of its industry peers.
A Quick Ratio of 0.90 indicates that ALVIO may have some problems paying its short term obligations.
The Quick ratio of ALVIO (0.90) is worse than 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.9
ALVIO.PA Yearly Current Assets VS Current LiabilitesALVIO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.63% over the past year.
Looking at the last year, ALVIO shows a very strong growth in Revenue. The Revenue has grown by 31.18%.
The Revenue for ALVIO have been decreasing by -21.74% on average. This is quite bad
EPS 1Y (TTM)31.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)31.18%
Revenue growth 3Y0.37%
Revenue growth 5Y-21.74%
Sales Q2Q%N/A

3.2 Future

ALVIO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -33.68% yearly.
The Revenue is expected to decrease by -29.53% on average over the next years. This is quite bad
EPS Next Y-136.11%
EPS Next 2Y-50.92%
EPS Next 3Y-33.68%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-29.53%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ALVIO.PA Yearly Revenue VS EstimatesALVIO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2026 20M 40M 60M
ALVIO.PA Yearly EPS VS EstimatesALVIO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 -0.2 0.4 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALVIO. In the last year negative earnings were reported.
Also next year ALVIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALVIO.PA Price Earnings VS Forward Price EarningsALVIO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALVIO.PA Per share dataALVIO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1

4.3 Compensation for Growth

A cheap valuation may be justified as ALVIO's earnings are expected to decrease with -33.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-50.92%
EPS Next 3Y-33.68%

More info and screens

0

5. Dividend

5.1 Amount

ALVIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALERIO TX

EPA:ALVIO (7/11/2025, 7:00:00 PM)

0.053

0 (-8.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)08-01 2025-08-01
Inst Owners28.6%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap8.18M
Analysts34.29
Price Target0.01 (-81.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.33
P/FCF N/A
P/OCF N/A
P/B 2.03
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0.01
BVpS0.03
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67%
ROE -488.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.75%
FCFM N/A
ROA(3y)-38.08%
ROA(5y)-40.32%
ROE(3y)-81.06%
ROE(5y)-87.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.31%
GM growth 5Y-6.1%
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 2.88
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 6.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.9
Quick Ratio 0.9
Altman-Z -4.06
F-Score3
WACC7.06%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)15.88%
Cap/Sales(5y)11.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y-136.11%
EPS Next 2Y-50.92%
EPS Next 3Y-33.68%
EPS Next 5YN/A
Revenue 1Y (TTM)31.18%
Revenue growth 3Y0.37%
Revenue growth 5Y-21.74%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-29.53%
Revenue Next 5YN/A
EBIT growth 1Y5.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-147.5%
EBIT Next 3Y-37.95%
EBIT Next 5YN/A
FCF growth 1Y-137.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.35%
OCF growth 3YN/A
OCF growth 5YN/A